Tom Roddy has worked across many areas of the drug discovery pipeline over the past 20+ years, from pre-competitive academic collaborations to post-marketing studies. Previously, he was the Vice President of Metabolism and Proteomics at Agios Pharmaceuticals. During his tenure at Agios, he led the start of the External Innovation function. His career started at Genzyme and he has worked at several other companies such as Novartis Institutes for BioMedical Research, Merck, and Beryllium. He is an internationally recognized analytical scientist and an accomplished scientific team builder and mentor, having led many successful biomarker, analytical, and target discovery teams. He is an author on ~80 publications in research focused on disease biology, pharmacology, and analytical sciences and has been a successful collaborator with leading global academic groups and CROs in the understanding of the mechanisms and physiology of existing and novel metabolism-based therapies. He has made translational contributions to Fabrazyme, Myozyme, Anacetrapib, Idhifa, Tibsovo, Ivosidenib, and Mitapivat.
Tom received his PhD in Chemistry from The Pennsylvania State University, an MS in Chemistry from Villanova University, and a BS in Chemistry from Juniata College.